Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Nightingale secured a 0.7 MEUR agreement for the Italian Moli-sani study

By Frans-Mikael RostedtAnalyst
Nightingale Health

Translation: Original published in Finnish on 07/07/2025 at 09:03 am EEST

Nightingale was selected as the metabolomics analysis provider for the renowned Moli-sani study in Italy. The total value of the agreement is approximately EUR 728, and the service is planned to be implemented already by the end of 2025. The agreement is significant for the company's research business and supports our growth forecasts for the second half of 2025. The company's revenue from other European countries (including Italy) was some 0.8 MEUR in 2024, making the agreement a significant size in comparison. This is a project-based revenue item, but we believe the agreement is a good additional reference for Nightingale's technology.

The Moli-sani study, led by INM Neuromed, investigates risk factors associated with major chronic diseases. With Nightingale Health’s advanced technology, the study will now examine the impact of nutritional and environmental factors on health.   The study also explores biological signatures associated with healthy aging and aims to identify population subgroups with different responses to preventative interventions. Nightingale was selected for the project in accordance with Italian public procurement law, and the parties are now proceeding to finalize the service agreement.

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures2025-06-11

202425e26e
Revenue4.45.28.2
growth-%4.2 %19.5 %57.5 %
EBIT (adj.)-18.6-17.3-16.2
EBIT-% (adj.)-426.6 %-331.4 %-197.6 %
EPS (adj.)-0.29-0.27-0.25
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Inderes Lääkinnällisen laitteen tiekartta Yhdysvaltojen markkinoille - Inderes Menestys Yhdysvalloissa edellyttää onnistumisia useilla osaalueilla...
12 hours ago
by Pertti
4
A recording of the event is also available:
3/24/2026, 3:11 PM
by Monsieur
4
Suna has been invited to New York by Google for Health LinkedIn 🚀 A few inspiring days in New York City last week. I joined Google’s Check.....
3/24/2026, 2:26 PM
by Monsieur
9
I don’t want to be nosy. (However) I am. Could you shed any light (in the spirit of elaborating) on why you breathed a sigh of relief in a situation...
3/13/2026, 8:02 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
1
Yeah, Tuukka jumped straight onto Bioretec’s lists, and I breathed a sigh of relief at that point myself.
3/13/2026, 5:09 PM
by Ossi
1
Although I was a long-time NGH believer, I have been shouting here about Tuukka Paavola’s suspicious, hasty departure from the CFO position ...
3/13/2026, 3:27 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
4
Indonesia in focus. LinkedIn #sevenstonesmarketentryindonesia #asianinsiders #markkinavalinta... Indonesian terveydenhuollon mittakaava on megalomaani...
3/13/2026, 9:13 AM
by Pertti
8
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.